Previously submitted to: JMIR Formative Research (no longer under consideration since Jan 25, 2024)
Date Submitted: May 15, 2023
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Clinical Outcomes in Vaccinated and Unvaccinated COVID-19 Inpatient Admissions March to September 2021: A Single Center Retrospective Cohort Analysis
ABSTRACT
Background:
COVID-19 is an international public health emergency. Despite challenging initial months plagued by death and uncertainty, the national scientific community developed a set of effective vaccines against the virus. The United States received early and consistent access relative to less industrialized countries. Despite this, vaccination rates in the United States have not been as robust. As SARS-CoV-2 variants developed, the prospect of vaccine-mediated immunity in the face of emerging variants remains guarded. What’s more, surges in COVID-19 cases in vaccinated patients gave pause to consider the underlying cause.
Objective:
To identify the effectiveness of Covid vaccination strategies in adult inpatient admissions.
Methods:
Retrospective cohort analysis of Emanate Health hospital system from March - September 2021. Demographic and clinical factors for adult inpatient COVID-19 positive admissions were analyzed using Meditech software. These included age, sex, comorbidities, date of admission, and immunization status. Immunization status was confirmed via the California Immunization Registry. Virus subtype and immunization status was not an exclusion criterion.
Results:
A total of 475 COVID positive adult inpatient admissions were analyzed. Of the total population sample, 28% of patients were vaccinated and 72% were unvaccinated. Inpatient admissions steadily decreased from March to June 2021, followed by steep increases from June to August 2021 driven predominately by unvaccinated patients. Length of stay was statistically significantly higher for patients 60-79 years old (P = .003) and in patients with four and six comorbidities (P = .002). Mortality was 1.5 times more likely in patients aged 60-79 years (P< .001) and 1.3 times more likely in those with 4 and 6 comorbid conditions (P = .002). Partially vaccinated individuals were admitted earlier to the hospital compared to fully vaccinated individuals (P< .001) and were more likely to require ICU admission and ventilation (P = .018). ICU admission was significantly higher in males compared to females (P = .027). Patients requiring an intensive care unit (ICU) admission and mechanical ventilation had a significantly higher mortality rate compared to those not requiring ICU admission or mechanical ventilation (P< .001).
Conclusions:
Our institutional data demonstrates strong trends previously described in national literature, including poor outcomes in unvaccinated, older patients, and those with multiple comorbid conditions. Fully vaccinated individuals had a shorter length of stay, irrespective of vaccine type. Mortality increased with age and was highest in patients 60-79 years old. In vaccinated patients, the top three comorbidities with the highest admission and mortality rates were hypertension, diabetes mellitus, and obesity, raising further questions regarding risk profiles in COVID-19 hospitalizations. Furthermore, COVID infection rates in vaccinated patients were lowest at 2 months and highest at <14 days and 5 months post-vaccination providing insight into the development and waning of immunity.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.